RT Book, Section
A1 Cain, Hilary C.
A2 Grippi, Michael A.
A2 Antin-Ozerkis, Danielle E.
A2 Dela Cruz, Charles S.
A2 Kotloff, Robert M.
A2 Kotton, Camille Nelson
A2 Pack, Allan I.
SR Print(0)
ID 1195007021
T1 Drug-induced Pulmonary Disease Due to Nonchemotherapeutic Agents
T2 Fishman’s Pulmonary Diseases and Disorders, 6e
YR 2023
FD 2023
PB McGraw-Hill Education
PP New York, NY
SN 9781260473988
LK accessmedicine.mhmedical.com/content.aspx?aid=1195007021
RD 2024/04/19
AB Medications  have  long  been  recognized  as  having  the  potential  to  cause  pulmonary  injury  even  when  given  at  therapeutic  doses.  The  precise  incidence  of  drug-induced  respiratory  disease  is  difficult  to  ascertain  and  potentially  is  confounded  by  reporting  bias  for  positive  events;  the  signs  and  symptoms  of  lung  toxicity  are  shared  by  many  other  pulmonary  conditions  and  diseases.  Data  on  adverse  events  are  supplied  to  national  databases  such  as  the  U.S.  Food  and  Drug  Administration  Adverse  Event  Reporting  System  (FAERS)  and  the  Japanese  Adverse  Event  Report  (JADER),  and  these  databases  can  be  utilized  to  determine  patterns  and  incidence  of  events.  However,  these  databases  are  limited  by  data  input,  and  concerns  inevitably  are  raised  about  the  completeness  and  accuracy  of  direct  submissions  from  providers  and  healthcare  facilities  compared  with  those  from  drug  manufacturers.1,2  As  the  categories  and  varieties  of  therapeutic  drugs  continue  to  increase,  clinicians  will  encounter  disease  from  new  culprit  drugs  in  addition  to  well-established  drug  reactions.  A  web-based  data  repository,  Pneumotox  V2.2  (www.pneumotox.com),  is  a  useful  tool  for  the  clinician,  as  it  provides  frequent  updates  based  on  the  emerging  literature  on  drug-induced  respiratory  toxicities.